Prograf + Methotrexate + Cyclosporine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Graft Versus Host Disease
Conditions
Graft Versus Host Disease
Trial Timeline
Feb 1, 2008 → Feb 1, 2010
NCT ID
NCT02660684About Prograf + Methotrexate + Cyclosporine
Prograf + Methotrexate + Cyclosporine is a approved stage product being developed by Astellas Pharma for Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02660684. Target conditions include Graft Versus Host Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02660684 | Approved | Completed |
Competing Products
20 competing products in Graft Versus Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alefacept | Astellas Pharma | Phase 2 | 52 |
| tacrolimus | Astellas Pharma | Approved | 85 |
| Tacrolimus + Tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Itolizumab + EQ001 Placebo | Biocon | Phase 3 | 77 |
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 41 |
| SHR0302 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Acalabrutinib | AstraZeneca | Phase 2 | 52 |
| Aspirin + Ticagrelor | AstraZeneca | Approved | 85 |
| Sugammadex | Merck | Approved | 85 |
| Efprezimod alfa + Methotrexate + Tacrolimus + Placebo | Merck | Phase 2 | 52 |
| Ruxolitinib | Novartis | Approved | 85 |
| Imatinib Mesylate and Nilotinib | Novartis | Phase 2 | 52 |
| Prednisone + Jakavi(ruxolitinib) + Prednisone | Novartis | Phase 2 | 52 |
| PredEver | Novartis | Phase 2 | 52 |
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 33 |
| Cyclosporine | Novartis | Approved | 85 |
| Everolimus + Tacrolimus + Mycophenolic acid | Novartis | Approved | 85 |
| 1 + 2 | Novartis | Approved | 85 |
| Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte Globulin | Novartis | Approved | 85 |